Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smallpox Drug Development May Get Boost From FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency convenes workshop to discuss use of animal models to demonstrate efficacy.
Advertisement

Related Content

Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
Smallpox Treatments: Are Monkeypox Or Mousepox Acceptable Substitutes For Studying The Virus?
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents
FDA Animal Efficacy Rule Drops Superiority Requirement For New Agents

Topics

Advertisement
UsernamePublicRestriction

Register

PS069856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel